Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918823 · ClinicalTrials.gov registry record · Phase 1
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device
A Phase 1 study, sponsored by Boston Sight.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04918823 is a Phase 1 study that has completed, run by Boston Sight. The registered enrollment target is 10 participants.
The verdict
NCT04918823, a Phase 1 study, has completed, sponsored by Boston Sight.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.
Interventions
- DRUG Restasis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04918823
The ClinicalTrials.gov registry entry for NCT04918823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Sight, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Restasis is the first listed.
NCT04918823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04918823 about?
NCT04918823 is a clinical study titled "Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device". The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Second...
What is the current status of trial NCT04918823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-07-15. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04918823?
The interventions under investigation include: Restasis (DRUG).
Who is sponsoring clinical trial NCT04918823?
This trial is sponsored by Boston Sight, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.